Molecular profiling of the immune response in colon cancer using protein microarrays: Occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3

被引:94
作者
Nam, MJ
Madoz-Gurpide, J
Wang, H
Lescure, P
Schmalbach, CE
Zhao, R
Misek, DE
Kuick, R
Brenner, DE
Hanash, SM
机构
[1] Univ Michigan, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA
关键词
autoantibodies; colon cancer; mass spectrometry; protein microarrays;
D O I
10.1002/pmic.200300594
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
We implemented a protein microarray approach to identify proteins that induce a humoral response in colon cancer. Solubilized proteins from the LoVo colon adenocarcinoma cell line were separated into 1760 fractions, arrayed onto nitrocellulose-coated slides, and hybridized with individual sera from 15 newly diagnosed patients with colon cancer, 15 with lung cancer, and 15 healthy subjects. 39/1760 fractions showed enhanced reactivity with sera from patients with colon cancer (P < 0.01) relative to healthy controls. A distinct pattern of reactivity was observed with sera from colon cancer relative to lung cancer. One fraction that exhibited reactivity with 9/15 colon cancer sera was subjected to mass spectrometry leading to the identification of ubiquitin C-terminal hydrolase isozyme 3 (UCH-L3) as a constituent. To validate the occurrence of autoantibodies to UCH-L3, independent analysis was done by means of Western blots. UCH-L3 antibodies were detected in 19/43 sera from patients with colon cancer, and in 0/54 sera from subjects with lung cancer (24), colon adenoma (15) or otherwise healthy (15). Our findings indicate the occurrence of an immune response to a broad set of antigens in colon cancer and the feasibility of identifying the antigenic targets using a combination of protein microarrays; and mass spectrometry.
引用
收藏
页码:2108 / 2115
页数:8
相关论文
共 34 条
[1]   Tumor antigens [J].
Boon, T ;
Old, LJ .
CURRENT OPINION IN IMMUNOLOGY, 1997, 9 (05) :681-683
[2]   Role of amplified genes in the production of autoantibodies [J].
Brass, N ;
Rácz, A ;
Bauer, C ;
Heckel, D ;
Sybrecht, G ;
Meese, E .
BLOOD, 1999, 93 (07) :2158-2166
[3]  
Brichory F, 2001, CANCER RES, V61, P7908
[4]  
DISIS ML, 1994, CANCER RES, V54, P16
[5]   Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles [J].
Giordano, TJ ;
Shedden, KA ;
Schwartz, DR ;
Kuick, R ;
Taylor, JMG ;
Lee, N ;
Misek, DE ;
Greenson, JK ;
Kardia, SLR ;
Beer, DG ;
Rennert, G ;
Cho, KR ;
Gruber, SB ;
Fearon, ER ;
Hanash, S .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 159 (04) :1231-1238
[6]  
Güre AO, 1998, CANCER RES, V58, P1034
[7]  
Haab BB, 2001, GENOME BIOL, V2
[8]  
Hallak R, 1998, INT J ONCOL, V12, P785
[9]   PGP9.5 as a candidate tumor marker for non-small-cell lung cancer [J].
Hibi, K ;
Westra, WH ;
Borges, M ;
Goodman, S ;
Sidransky, D ;
Jen, J .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (03) :711-715
[10]   Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1:: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes [J].
Jäger, E ;
Chen, YT ;
Drijfhout, JW ;
Karbach, J ;
Ringhoffer, M ;
Jäger, D ;
Arand, M ;
Wada, H ;
Noguchi, Y ;
Stockert, E ;
Old, LJ ;
Knuth, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (02) :265-270